Citations 1
Ruxolitinib is more effective than other JAK inhibitors to treat VEXAS syndrome: a retrospective multicenter study
Heiblig, Maël , Ferrada, Marcela A. , Koster, Matthew T., Barba, Thomas , Gerfaud‐Valentin, Mathieu , Mékinian, A. , Coelho, Henrique , Fossard, Gaëlle , Barraco, Fiorenza , Galicier, Lionel , Bienvenu, Boris , Hirsch, Pierre , Vial, Guillaume , Boutin, Anne Blandine, Guenno, G. Le , Bigot, Adrien , Kermani, Tanaz A. , Grayson, Peter C. , Beck, David B. , Fenaux, Pierre , Sujobert, Pierre , Mékinian, Arsène , Galland, Joris , Le Guenno, Guillaume , Bigot, Adrien , Jamilloux, Yvan , Heiblig, Mael , Ferrada, Marcela A , Koster, Matthew, Warrington, Kenneth J. , Patel, Bhavisha A.
Blood | May 24, 2022 | Volume: 140 | Issue: 8 | Pages: 927-931
VEXAS syndrome (vacuoles in myeloid progenitors, E1 ubiquitin activating enzyme, X-linked, autoinflammatory manifestations and somatic) is an autoinflammatory condition caused by somatically acquired UBA1 mutations. Heiblig et al report on an international retrospective analysis of 30 patients with VEXAS syndrome treated with different Janus kinase (JAK) inhibitors, finding encouraging evidence supporting the use of the JAK1/2 inhibitor ruxolitinib with clinical remissions and reductions in steroid use seen in the majority of patients.